Powder: -20°C for 3 years | In solvent: -80°C for 1 year
(E/Z)-BCI (NSC-150117) 是一种DUSP6抑制剂,可通过激活 Nrf2 信号和抑制 NF-κB 通路,减弱 LPS 诱导的巨噬细胞炎症和 ROS 生成,具有抗炎活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 917 | 现货 | ||
5 mg | ¥ 2,280 | 现货 | ||
10 mg | ¥ 3,750 | 现货 | ||
25 mg | ¥ 6,380 | 现货 | ||
50 mg | ¥ 8,730 | 现货 | ||
100 mg | ¥ 11,700 | 现货 | ||
500 mg | ¥ 23,600 | 待询 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,980 | 现货 |
产品描述 | (E/Z)-BCI (NSC-150117), a dual-specificity phosphatase 6 (DUSP6) inhibitor with anti-inflammatory properties, reduces LPS-induced inflammatory mediators and ROS production in macrophage cells by activating the Nrf2 signaling axis and inhibiting the NF-κB pathway. |
体外活性 | (E/Z)-BCI hydrochloride (2-10 μM;?72 hours) significantly decreases cell viability in a time and dose-dependent manner in gastric epithelial cell GES1, GC cell lines, and AGS cell lines.?(E/Z)-BCI hydrochloride (0.5-4 μM;?24 hours) significantly inhibits DUSP6 expression in LPS-activated macrophages. (E/Z)-BCI hydrochloride inhibits cell proliferation, migration, and invasion in a receptor-independent manner and enhances Cisplatin (CDDP) cytotoxicity (enhances CDDP-induced cell death and apoptosis) at pharmacological concentrations in gastric cancer (GC) cells.?(E/Z)-BCI hydrochloride (0.5-2 μM;?24 hours) treatment significantly inhibits the expression of IL-1β, TNF-α, and IL-6 mRNA in LPS-activated macrophages.?(E/Z)-BCI hydrochloride decreases ROS production and activates the Nrf2 pathway in LPS-activated macrophages.? |
体内活性 | (E/Z)-BCI hydrochloride treatment enhances cisplatin efficacy in PDX models. |
别名 | NSC 150117 |
分子量 | 317.42 |
分子式 | C22H23NO |
CAS No. | 15982-84-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 20mg/mL (60.00mM), sonification is recommended.
DMSO: 60mg/mL (189.02mM), sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 3.1504 mL | 15.752 mL | 31.504 mL | 78.76 mL |
5 mM | 0.6301 mL | 3.1504 mL | 6.3008 mL | 15.752 mL | |
10 mM | 0.315 mL | 1.5752 mL | 3.1504 mL | 7.876 mL | |
20 mM | 0.1575 mL | 0.7876 mL | 1.5752 mL | 3.938 mL | |
50 mM | 0.063 mL | 0.315 mL | 0.6301 mL | 1.5752 mL | |
DMSO | 100 mM | 0.0315 mL | 0.1575 mL | 0.315 mL | 0.7876 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
(E/Z)-BCI 15982-84-0 Apoptosis Metabolism Phosphatase NSC150117 ROS NSC 150117 death LPS gastric cancer anti-inflammatory NF-κB inhibit Inhibitor (E/Z) BCI Nrf2 (E/Z)BCI NSC-150117 ERK DUSP6 inhibitor